Navigation Links
Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities
Date:8/3/2011

NEW YORK, Aug. 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarkers: Technological and Commercial Outlook 2011-2021 - discovering the pharma and diagnostics opportunities

http://www.reportlinker.com/p0578545/Biomarkers-Technological-and-Commercial-Outlook-2011-2021---discovering-the-pharma-and-diagnostics-opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

What are the commercial prospects for biomarkers in pharma and diagnostics? Our new report shows you commercial opportunities for biomarkers, predicting future trends. Through our research and analysis we aim to save you time and help in your decisions.

You will find revenue forecasts to 2021 at overall world, submarket and national levels. What technologies and applications will increase the use of biomarkers? What effects will changes and regulations have? You will find predictions and opportunities.

In our study you will find discussions of genomic and proteomic approaches to biomarker discovery, including metabolomics and microarray platforms. You will see how biomarker technologies are changing pharma and diagnostics. 

You will discover commercial activities of Affymetrix, Agilent, Stemina Biomarker Discovery, Crown Bioscience and other biomarker specialists. We also discuss the activities of Pfizer, J&J, GSK, Sanofi, Novartis, AstraZeneca, Roche and other pharma leaders. 

Our report shows you revenue predictions for biomarkers in oncology, cardiovascular and central nervous system applications. You will also see forecast revenues for genomics, proteomics and bioinformatics. We show you trends to watch.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Original analysis with revenues, growth rates, market shares, opinion and discussions

You will find revenue forecasts, growth rates, market shares, a SWOT/STEP review, opinions from our survey and discussions of technologies and companies. We provide 76 tables and charts and three research interviews (shown in the accompanying lists).

Biomarkers: Technological and Commercial Outlook 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

• You will discover revenue forecasts to 2021 for the world biomarkers market and its main components, seeing where the highest revenue growth will occur

• You will appraise the future of biomarkers research from scientific, technological and commercial perspectives, seeing R&D trends

• You will receive revenue forecasts for the leading therapeutic areas for biomarker technologies - oncology, cardiovascular diseases and CNS disorders - to 2021

• You will see forecast revenues for genomics, proteomics and bioinformatics to 2021

• You will find discussions of biomarker research and assess the importance of that work for patient stratification and targeted therapies

• You will receive revenue forecasts for the leading national markets for biomarkers to 2021 - the US, the UK, Canada, Germany, France, Spain, Italy, Japan, China and India - seeing growth prospects

• You will investigate activities of leading companies developing biomarkers

• You will assess the activities of leading pharmaceutical companies using biomarkers, reviewing partnerships with industry and academia

• You will investigate competition and opportunities influencing the industry and market from 2011 onwards

• You will see what will stimulate and restrain the industry and market from 2011

• You will analyse opportunities and challenges for established companies and those seeking to commercialise biomarkers

• You will view opinions from three interviews with authorities on biomarkers.

That mix of quantitative and qualitative analysis sets our report apart. We tackle crucial questions, helping you to stay ahead. You will discover trends in biomarkers through predictions found only in our work.

Order our report now to gain industry and market analysis for biomarkers

Our report is for essential for anyone interested in biomarkers, drug development, medical diagnostics and personalised medicine. You will find predictions and answers. Don't miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs

Table of Contents

1. Executive Summary

1.1 Review of the World Biomarkers Market

1.2 Aims, Scope and Format of the Report

1.3 Research and Analysis Methods

2. Introduction to Biomarkers and Their Applications

2.1 Introduction

2.2 The Discovery and Validation of Novel Biomarkers

2.2.1 The Discovery of Novel Biomarkers

2.2.2 The Verification of Biomarkers

2.2.3 The Validation of Biomarkers

2.2.4 The Qualification of Biomarkers

2.3 The Importance of Biomarker Research

2.3.1 The Importance of Biomarkers for Patients

2.3.2 The Importance of Biomarkers in Pharmaceutical R&D

2.3.3 The Importance of Biomarkers for Regulatory Authorities

2.4 Applications of Biomarkers within the Global Healthcare System

2.4.1 Overview

2.4.2 Predictive Biomarkers for Assessing Drug Efficacy

2.4.3 Predictive Biomarkers for Assessing Drug Safety

2.4.4 Biomarkers for Clinical Prognosis

2.5 Imaging Biomarkers

2.5.1 A Brief History of Imaging Biomarkers

2.5.2 Importance of Imaging Biomarkers in Clinical Trials

2.5.3 Challenges with Using Imaging Biomarkers in Clinical Trials

2.5.4 Example of an Imaging Biomarker: Case of Parkinson's Disease

2.6 Genomic Biomarkers

2.6.1 Introduction

2.6.2 Genomic Biomarkers in Oncology

2.7 Companion Diagnostics

2.8 Personalised Medicine

2.9 The Impact of Biomarkers within the Pharmaceutical Industry

2.9.1 Introduction

2.9.2 Pfizer

2.9.3 Johnson & Johnson

2.9.4 GlaxoSmithKline

2.9.5 Sanofi

2.9.6 Novartis

2.9.7 AstraZeneca

2.9.8 Roche

2.9.9 Abbott Laboratories

2.9.10 Eli Lilly

2.9.11 Bristol-Myers Squibb

3. Technological Platforms for Biomarker Discovery and Leading Manufacturers, 2011

3.1 Introduction

3.2 Biomarker Discovery Technologies

3.2.1 Genomics Approaches to Biomarker Discovery

3.2.2 Proteomics Approaches to Biomarker Discovery

3.2.3 Metabolomics

3.2.4 Pharmacogenomics

3.2.5 Integrative Approaches

3.3 Leading Manufacturers of Biomarker Technologies

3.3.1 Affymetrix

3.3.1.1 Affymetrix GeneChip miRNA 2.0 Array

3.3.2 Agilent

3.3.2.1 Agilent's HPLC-Chip/6210 TOF MS

3.3.3 Stemina Biomarker Discovery

3.3.3.1 Stemina's DevTOX Assay

3.3.4 Crown Bioscience

3.4 The Future of Biomarker Discoveries

3.4.1 Microarray Platforms Have Been Overshadowed by Next-Generation Sequencing Technologies

3.4.2 Biomarker Discovery is Increasingly Happening Earlier in the Drug Discovery Process

3.4.3 Biomarkers Will Facilitate Patient Stratification - But What Does This Mean for the Blockbuster Model of Pharmaceutical Companies?

4. Overview of the World Biomarkers Market, 2011-2021

4.1 The World Biomarkers Market, 2011-2021

4.2 Oncology is a Rapidly Evolving Therapeutic Area for the Application of Biomarkers

4.3 Few Pharmaceutical Companies Have Dedicated Diagnostics Units: What Does This Mean for the Future of the Biomarkers Market?

4.4 The Current Model of Pharmaceutical R&D is Inefficient and Potentially a Restraint in Accelerating the Discovery of Novel Biomarkers and Drugs

5. Analysis of the World Biomarkers Market, 2011-2021

5.1 The World Biomarkers Market, 2010

5.2 The World Biomarkers Market, 2010-2015

5.3 The World Biomarkers Market, 2016-2021

5.4 Leading Therapeutic Areas within the World Biomarkers Market, 2010-2021

5.4.1 Overview

5.5 The Oncology Biomarkers Market, 2010-2021

5.5.1 The Oncology Biomarkers Market, 2010

5.5.2 The Oncology Biomarkers Market, 2010-2015

5.5.3 The Oncology Biomarkers Market, 2016-2021

5.6 Cardiovascular Biomarkers Market, 2010-2021

5.6.1 The Cardiovascular Biomarkers Market, 2010

5.6.2 The Cardiovascular Biomarkers Market, 2010-2015

5.6.3 The Cardiovascular Biomarkers Market, 2016-2021

5.7 Central Nervous System Biomarkers Market, 2010-2021

5.7.1 The Central Nervous System Biomarkers Market, 2010

5.7.2 The Central Nervous System Biomarkers Market, 2010-2015

5.7.3 The Central Nervous System Biomarkers Market, 2016-2021

5.8 Markets Driving Innovation in Biomarker Discovery, 2010-2021

5.8.1 Overview of Markets Driving Innovation in Biomarker Discovery, 2010

5.8.2 Proteomics and Biomarker Discovery, 2010-2021

5.8.2.1 Proteomics Market, 2010-2015

5.8.2.2 Proteomics Market, 2016-2021

5.8.3 Genomic Sequencing and Biomarker Discovery, 2010-2021

5.8.3.1 Genomic Sequencing Market, 2010-2015

5.8.3.2 Genomic Sequencing Market, 2016-2021

5.8.4 Bioinformatics and Biomarker Discovery, 2010-2021

5.8.4.1 Bioinformatics Market, 2010-2015

5.8.4.2 Bioinformatics Market, 2016-2021

6. Leading National Markets for Biomarkers, 2011-2021

6.1 Leading National Markets for Biomarker Research, 2010

6.2 Forecasts for the Leading National Markets for Biomarker Research, 2010-2021

6.2.1 The US Biomarkers Market, 2010-2021

6.2.2 The UK Biomarkers Market, 2010-2021

6.2.3 Other Leading European Markets for Biomarkers, 2010-2021

6.2.4 The Japanese Biomarkers Market, 2010-2021

6.2.5 The Chinese Biomarkers Market, 2010-2021

6.2.6 The Indian Biomarkers Market, 2010-2021

7. Analysis of Factors Influencing the World Biomarkers Market, 2011-2021

7.1 SWOT Analysis of the World Biomarkers Market

7.2 Drivers of the World Biomarkers Market

7.2.1 Biomarkers Have Great Usefulness in Drug Discovery Programmes

7.2.2 Biomarkers Facilitate Patient Stratification

7.2.3 Regulatory Agencies Recognise Biomarkers as Important for Innovation in Drug Discovery

7.2.4 The Declining Cost of Human Genome Sequencing Will Facilitate Discoveries in Biomarkers for Areas Such as Oncology

7.3 Restraints in the World Biomarkers Market

7.3.1 The Field of Diagnostics Has Traditionally Been an Undervalued Area of Science When Compared with the Production of Chemical Products

7.3.2 Advances in Biomarker Research Made Difficult by Publication Bias?

7.3.3 Types of Proteins Studied by Structural Biologists Have Changed Relatively Little over the Past Decade

7.3.4 Lack of Clear Regulatory Guidelines on Companion Diagnostics

7.4 Outlook for the World Biomarkers Market

7.4.1 Data Storage and Handling Will Be Important Factors Determining Future Growth in the Biomarkers Market

7.4.2 Public-Private Partnerships Will Increase the Efficiency of Biomarker Discovery and Validation

7.4.3 Targeted Therapies Will Revolutionise the Current Model of Pharmaceutical R&D

8. Research Interviews with Authorities on Biomarkers

8.1 Interview with Professor Philip Scheltens, Clinical Neurologist and Director of the Alzheimer Center, Vrije Universiteit Medical Center, Netherlands

8.1.1 The Underlying Causes of Alzheimer's Disease and Available Therapies

8.1.2 Research at the Alzheimer Center of Vrije Universiteit Medical Center

8.1.3 Biomarker Discovery and Translational Medicine

8.1.4 The Future of Alzheimer's Research

8.2 Interview with Dr Jean-Pierre Wery, President, Crown Bioscience, China

8.2.1 Contract Research Services Offered by Crown Bioscience

8.2.2 Technological Platforms and Animal Models Available for Clients

8.2.3 Range of Therapeutic Areas Covered by Crown Bioscience

8.2.4 Translational Medicine and Patient Stratification

8.2.5 Outlook

8.3 Interview with Professor Herbie Newell, Professor of Cancer Therapeutics, Northern Institute for Cancer Research, University of Newcastle, UK

8.3.1 The Importance of Biomarkers for Cancer Therapy

8.3.2 Technological Platforms Used in the Discovery of Novel Biomarkers

8.3.3 The Challenges in Transferring Cancer Biomarker Discoveries to the Clinic

8.3.4 Cancer Heterogeneity and Targeted Therapy

8.3.5 Reform in Pharmaceutical R&D and the Importance of Public-Private Partnerships

8.3.6 Current Trends and the Future of Cancer Research

9. Outlook for the World Biomarkers Market, 2011-2021

9.1 Non-Invasive Biomarkers are Expected to Drive Growth in the World Biomarkers Market

9.2 The Expected Healthcare Applications of Whole-Genome Sequencing Will Drive Growth in the Approval and Use of Biomarkers

9.3 Data Storage and Handling are Increasingly Limiting Factors in Genomics: Will this Affect Discoveries in Biomarker Research?

9.4 The US and UK Dominate the World Biomarkers Market

9.5 Promising Biomarker Products for Oncology, Cardiovascular and Central Nervous System Disorders

9.5.1 Pentraxin-3 as a Biomarker for Lung Carcinoma: Example of a Novel Oncology Biomarker

9.5.2 YKL-40 as a Biomarker for Ischaemic Heart Disease: Example of a Novel Cardiovascular Biomarker

9.5.3 Biomarkers Derived from CSF: The Utility of Amyloid and Tau Protein as Biomarkers for Alzheimer's Disease

10. Conclusions

10.1 The World Biomarkers Market Will Achieve Sustained Growth from 2011-2021

10.2 Biomarker Discoveries in Oncology Will be Aided by Technological Advances and the Insights from Cancer Genome Sequencing

10.3 China and India Have the Potential to Become Leading Centres of Genomic and Proteomic Analysis for Biomarker Discovery

10.4 Drug Developers and Manufacturers Need Expertise in Biomarker Discovery and Use

List of Tables

Table 2.1 Examples of Imaging Biomarkers for Parkinson's Disease, 2011

Table 2.2 Examples of Clinically Relevant Cancer Biomarkers, 2011

Table 3.1 Outline of Various Methods for Biomarker Discovery, 2011

Table 4.1 Leading Therapeutic Submarkets within the World Biomarkers Market ($bn), 2010-2015

Table 4.2 Leading Therapeutic Submarkets within the World Biomarkers Market ($bn), 2016-2021

Table 5.1 World Biomarkers Market ($bn), 2010-2015

Table 5.2 World Biomarkers Market ($bn), 2016-2021

Table 5.3 Market Shares (%) for the Leading Biomarker Markets, 2010-2015

Table 5.4 Market Shares (%) for the Leading Biomarker Markets, 2016-2021

Table 5.5 Oncology Biomarkers Market ($bn), 2010-2015

Table 5.6 Oncology Biomarkers Market ($bn), 2016-2021

Table 5.7 Cardiovascular Biomarkers Market ($bn), 2010-2015

Table 5.8 Cardiovascular Biomarkers Market ($bn), 2016-2021

Table 5.9 Biomarker Market ($bn) for Central Nervous System Disorders, 2010-2015

Table 5.10 Biomarker Market ($bn) for Central Nervous System Disorders, 2016-2021

Table 5.11 Markets ($bn) Driving Innovation in Biomarkers Discovery, 2010-2015

Table 5.12 Markets ($bn) Driving Innovation in Biomarkers Discovery, 2016-2021

Table 6.1 Leading National Markets ($bn) for Biomarkers, 2010

Table 6.2 Leading National Markets ($bn) for Biomarkers, 2010-2015

Table 6.3 Leading National Markets ($bn) for Biomarkers, 2016-2021

Table 6.4 The US Biomarkers Market ($bn), 2010-2015

Table 6.5 The US Biomarkers Market ($bn), 2016-2021

Table 6.6 National Market Shares (%) for the World Biomarkers Market, 2010, 2015 and 2021

Table 6.7 The UK Biomarkers Market ($bn), 2010-2015

Table 6.8 The UK Biomarkers Market ($bn), 2016-2021

Table 6.9 Other Leading European Markets ($bn) for Biomarkers, 2010-2015

Table 6.10 Other Leading European Markets ($bn) for Biomarkers, 2016-2021

Table 6.11The Japanese Biomarkers Market ($bn), 2010-2015

Table 6.12 The Japanese Biomarkers Market ($bn), 2016-2021

Table 6.13 The Chinese Biomarkers Market ($bn), 2010-2015

Table 6.14 The Chinese Biomarkers Market ($bn), 2016-2021

Table 6.15 The Indian Biomarkers Market ($bn), 2010-2015

Table 6.16 The Indian Biomarkers Market ($bn), 2016-2021

Table 7.1 SWOT Analysis of the World Biomarkers Market, 2011

Table 7.2 Average Cost ($m) of Human Genome Sequencing, 2000-2005

Table 7.3 Average Cost ($m) of Human Genome Sequencing, 2006-2011

Table 7.4 Average Cost ($) of Human Genome Sequencing, 2012-2017

Table 7.5 Average Cost ($) of Human Genome Sequencing, 2018-2021

Table 9.1 Forecast Revenues ($bn) for the Sale of Genomic Sequencing Technologies Used within the Global Healthcare Sector, 2010-2015

Table 9.2 Forecast Revenues ($bn) for the Sale of Genomic Sequencing Technologies Used within the Global Healthcare Sector, 2016-2021

List of Figures

Figure 2.1 How Biomarkers Can be Integrated within the Drug Discovery Process, 2011

Figure 4.1 Leading Therapeutic Submarkets within the World Biomarkers Market ($bn), 2010-2015

Figure 4.2 Leading Therapeutic Submarkets within the World Biomarkers Market ($bn), 2016-2021

Figure 5.1 World Market ($bn) for Biomarkers, 2010-2021

Figure 5.2 Shares (%) for the Leading Therapeutic Areas for Biomarker Products, 2010

Figure 5.3 Shares (%) for the Leading Therapeutic Areas for Biomarker Products, 2015

Figure 5.4 Shares (%) for the Leading Therapeutic Areas for Biomarker Products, 2021

Figure 5.5 Oncology Biomarkers Market ($bn), 2010-2015

Figure 5.6 Oncology Biomarkers Market ($bn), 2016-2021

Figure 5.7 Cardiovascular Biomarkers Market ($bn), 2010-2015

Figure 5.8 Cardiovascular Biomarkers Market ($bn), 2016-2021

Figure 5.9 Biomarkers Market ($bn) for Central Nervous System Disorders, 2010-2015

Figure 5.10 Biomarkers Market ($bn) for Central Nervous System Disorders, 2016-2021

Figure 5.11 Forecast Growth of the Proteomics Market ($bn), 2010-2015

Figure 5.12 Forecast Growth of the Proteomics Market ($bn), 2016-2021

Figure 5.13 Forecast Growth of the Genomics Market ($bn), 2010-2015

Figure 5.14 Forecast Growth of the Genomics Market ($bn), 2016-2021

Figure 5.15 Forecast Growth of the Bioinformatics Market ($bn), 2010-2015

Figure 5.16 Forecast Growth of the Bioinformatics Market ($bn), 2016-2021

Figure 6.1 Leading National Markets ($bn) for Biomarkers, 2010

Figure 6.2 The US Biomarkers Market ($bn), 2010-2015

Figure 6.3 The US Biomarkers Market ($bn), 2016-2021

Figure 6.4 National Market Shares (%) for the World Biomarkers Market, 2010

Figure 6.5 National Market Shares (%) for the World Biomarkers Market, 2015

Figure 6.6 National Market Shares (%) for the World Biomarkers Market, 2021

Figure 6.7 The UK Biomarkers Market ($bn), 2010-2015

Figure 6.8 The UK Biomarkers Market ($bn), 2016-2021

Figure 6.9 Other Leading European Markets ($bn) for Biomarkers, 2010-2015

Figure 6.10 Other Leading European Markets ($bn) for Biomarkers, 2016-2021

Figure 6.11 The Japanese Biomarkers Market ($bn), 2010-2015

Figure 6.12 The Japanese Biomarkers Market ($bn), 2016-2021

Figure 6.13 The Chinese Biomarkers Market ($bn), 2010-2015

Figure 6.14 The Chinese Biomarkers Market ($bn), 2016-2021

Figure 6.15 The Indian Biomarkers Market ($bn), 2010-2015

Figure 6.16 The Indian Biomarkers Market ($bn), 2016-2021

Figure 9.1 Sales ($bn) for Genomic Sequencing Technologies for Use within the World Healthcare Sector, 2010-2021

Companies Listed

Abbott Diagnostics

Abbott Laboratories

Affymetrix 

Agilent

Astellas Pharma

AstraZeneca

Allostem Therapeutics 

Alzheimer Center, Vrije Universiteit Medical Center, Netherlands

Alzheimer Disease International 

Alzheimer's Association 

Alzheimer's Research Trust

American Association for Cancer Research

American Heart Association 

Applied NeuroSolutions

ApoCell

Beth Israel Deaconess Medical Center

BGI

BG Medicine

Biomarkers Definitions Working Group

BioSite

Biotechnology Industry Organization

Bristol-Myers Squibb

Broad Institute 

Cancer Research Technology

Cancer Research UK

Caprion Proteomics

Celera

Center for Diseases Control and Prevention

Centers for Medicare & Medicaid Services

CIT

Clinical Trials Registry

Convergence Medical Devices

Crown Bioscience 

Dako 

DiaGenic

Eisai

Eli Lilly

EnVivo Pharmaceuticals

Epistem

European Medicines Agency (EMA)

Fred Hutchinson Cancer Research Centre

Food and Drug Administration (US FDA)

Foundation for the National Institutes of Health (FNIH)

GE Global Research

GE Healthcare

Genedata 

Genetic MicroSystems

GlaxoSmithKline

Harvard Medical School

Harvard University

Hewlett-Packard

Human Genome Project

Human Metabolome Technologies

Illumina

Industry Pharmacogenomics Working Group (I-PWG)

International Conference on Harmonisation (ICH)

Ion Torrent

John Hopkins University

Johnson & Johnson 

KineMed

MD Anderson Cancer Center

Medical Research Council (MRC)

Medicines and Healthcare Products Regulatory Agency (MHRA) 

Memory Pharmaceuticals

Merck & Co.

Millennium Genome Project

Ministry of Health and Welfare (Japan)

MIT

Monogram BioSciences

Mount Sinai Hospital

National Academy of Sciences

National Institute on Aging

National Institutes of Health (US) 

Neomorphic 

Northern Institute for Cancer Research (NICR), University of Newcastle, UK

Novartis

Novartis Institutes for BioMedical Research (NIBR)

Novartis Molecular Diagnostics

Nymox Pharmaceuticals 

Solvay

Structural Genomics Consortium (SGC)

Panomics 

ParAllele BioScience 

Peterson Institute for Cancer Research

Pfizer

Pharmaceutical Research and Manufacturers of America

PPD

Prize4Life

Provista Life Sciences

Qiagen

RIKEN Center for Genomic Medicine

Roche

Roche Molecular Diagnostics

Sanofi

Satoris

Stemina

Structural Genomics Consortium 

Takeda

The Biomarkers Consortium

The Genome Institute of Washington University

True Materials 

Tufts Center for the Study of Drug Development

University of Birmingham 

University of California 

University of Montpellier 

University of Newcastle

University of Oxford

University of Texas

University of Toronto

USB Corporation

US Secretary's Advisory Committee on Genetics, Health and Society (SACGHS)

US Department of Health and Human Services (HSS)

Vrije Universiteit Medical Center

Washington University

Welcome Trust Sanger Institute

World Health Organization 

Wyeth (now part of Pfizer)

To order this report:

Genomics Industry: Biomarkers: Technological and Commercial Outlook 2011-2021 - discovering the pharma and diagnostics opportunities

Genomics Business News

More  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Biomarkers: Discovery Techniques and Applications - A Global Market Overview
2. Reportlinker Adds Biomarkers: Technologies and Global Markets
3. Reportlinker Adds Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
4. Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018
5. New approaches, technological advances offer promise for obesity treatment
6. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
7. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
8. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
9. Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy
10. CMS, Inc., an Elekta Company, Announces Commercial Availability of Focal4D(TM)
11. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
Breaking Biology Technology:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):